1. Home
  2. ATNM vs MYND Comparison

ATNM vs MYND Comparison

Compare ATNM & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • MYND
  • Stock Information
  • Founded
  • ATNM 2000
  • MYND 1998
  • Country
  • ATNM United States
  • MYND Cayman Islands
  • Employees
  • ATNM N/A
  • MYND N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • MYND Other Consumer Services
  • Sector
  • ATNM Health Care
  • MYND Real Estate
  • Exchange
  • ATNM Nasdaq
  • MYND Nasdaq
  • Market Cap
  • ATNM 56.5M
  • MYND 60.3M
  • IPO Year
  • ATNM N/A
  • MYND 2017
  • Fundamental
  • Price
  • ATNM $1.73
  • MYND $1.31
  • Analyst Decision
  • ATNM Strong Buy
  • MYND
  • Analyst Count
  • ATNM 5
  • MYND 0
  • Target Price
  • ATNM $14.20
  • MYND N/A
  • AVG Volume (30 Days)
  • ATNM 285.8K
  • MYND 254.9K
  • Earning Date
  • ATNM 10-31-2024
  • MYND 11-03-2024
  • Dividend Yield
  • ATNM N/A
  • MYND N/A
  • EPS Growth
  • ATNM N/A
  • MYND N/A
  • EPS
  • ATNM N/A
  • MYND N/A
  • Revenue
  • ATNM $81,000.00
  • MYND $357,050,000.00
  • Revenue This Year
  • ATNM $186.10
  • MYND N/A
  • Revenue Next Year
  • ATNM $19,248.94
  • MYND N/A
  • P/E Ratio
  • ATNM N/A
  • MYND N/A
  • Revenue Growth
  • ATNM 80.00
  • MYND N/A
  • 52 Week Low
  • ATNM $1.33
  • MYND $0.61
  • 52 Week High
  • ATNM $10.24
  • MYND $14.20
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 41.48
  • MYND 56.29
  • Support Level
  • ATNM $1.48
  • MYND $0.61
  • Resistance Level
  • ATNM $1.80
  • MYND $1.40
  • Average True Range (ATR)
  • ATNM 0.12
  • MYND 0.19
  • MACD
  • ATNM 0.04
  • MYND 0.08
  • Stochastic Oscillator
  • ATNM 54.44
  • MYND 58.79

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About MYND Mynd.ai Inc.

Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more.

Share on Social Networks: